Compare WNC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | RCKT |
|---|---|---|
| Founded | 1985 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.2M | 534.2M |
| IPO Year | 2009 | N/A |
| Metric | WNC | RCKT |
|---|---|---|
| Price | $8.96 | $3.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $11.00 | ★ $29.73 |
| AVG Volume (30 Days) | 460.6K | ★ 4.2M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 179.22 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $2,027,489,000.00 | N/A |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $14.06 | $69.83 |
| P/E Ratio | $1.84 | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $6.78 | $2.19 |
| 52 Week High | $12.94 | $8.26 |
| Indicator | WNC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 48.29 |
| Support Level | $8.58 | $2.99 |
| Resistance Level | $9.33 | $4.08 |
| Average True Range (ATR) | 0.37 | 0.31 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 66.28 | 27.86 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.